Literature DB >> 17828757

Heterogeneity of monoclonal antibodies.

Hongcheng Liu1, Georgeen Gaza-Bulseco, Dinesh Faldu, Chris Chumsae, Joanne Sun.   

Abstract

Heterogeneity of monoclonal antibodies is common due to the various modifications introduced over the lifespan of the molecules from the point of synthesis to the point of complete clearance from the subjects. The vast number of modifications presents great challenge to the thorough characterization of the molecules. This article reviews the current knowledge of enzymatic and nonenzymatic modifications of monoclonal antibodies including the common ones such as incomplete disulfide bond formation, glycosylation, N-terminal pyroglutamine cyclization, C-terminal lysine processing, deamidation, isomerization, and oxidation, and less common ones such as modification of the N-terminal amino acids by maleuric acid and amidation of the C-terminal amino acid. In addition, noncovalent associations with other molecules, conformational diversity and aggregation of monoclonal antibodies are also discussed. Through a complete understanding of the heterogeneity of monoclonal antibodies, strategies can be employed to better identify the potential modifications and thoroughly characterize the molecules.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17828757     DOI: 10.1002/jps.21180

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  107 in total

1.  Structure and function of purified monoclonal antibody dimers induced by different stress conditions.

Authors:  Rajsekhar Paul; Alexandra Graff-Meyer; Henning Stahlberg; Matthias E Lauer; Arne C Rufer; Hermann Beck; Alexandre Briguet; Volker Schnaible; Thomas Buckel; Sabine Boeckle
Journal:  Pharm Res       Date:  2012-04-05       Impact factor: 4.200

Review 2.  Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents.

Authors:  Denise M O'Hara; Valerie Theobald; Adrienne Clements Egan; Joel Usansky; Murli Krishna; Julie TerWee; Mauricio Maia; Frank P Spriggs; John Kenney; Afshin Safavi; Jeannine Keefe
Journal:  AAPS J       Date:  2012-03-14       Impact factor: 4.009

Review 3.  Therapeutic proteins.

Authors:  Dimiter S Dimitrov
Journal:  Methods Mol Biol       Date:  2012

Review 4.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

5.  Therapeutic antibodies, vaccines and antibodyomes.

Authors:  Dimiter S Dimitrov
Journal:  MAbs       Date:  2010-05-14       Impact factor: 5.857

6.  Rapid quantitative analysis of monoclonal antibody heavy and light chain charge heterogeneity.

Authors:  Ram P Vanam; Michael A Schneider; Michael S Marlow
Journal:  MAbs       Date:  2015-08-25       Impact factor: 5.857

7.  Weak protein interactions and pH- and temperature-dependent aggregation of human Fc1.

Authors:  Haixia Wu; Kristopher Truncali; Julie Ritchie; Rachel Kroe-Barrett; Sanjaya Singh; Anne S Robinson; Christopher J Roberts
Journal:  MAbs       Date:  2015-08-12       Impact factor: 5.857

8.  Multifunctional Dendrimer-templated Antibody Presentation on Biosensor Surfaces for Improved Biomarker Detection.

Authors:  Hye Jung Han; Rangaramanujam M Kannan; Sunxi Wang; Guangzhao Mao; Juan Pedro Kusanovic; Roberto Romero
Journal:  Adv Funct Mater       Date:  2010-02-08       Impact factor: 18.808

9.  Characterization and comparison of disulfide linkages and scrambling patterns in therapeutic monoclonal antibodies: using LC-MS with electron transfer dissociation.

Authors:  Yi Wang; Qiaozhen Lu; Shiaw-Lin Wu; Barry L Karger; William S Hancock
Journal:  Anal Chem       Date:  2011-03-23       Impact factor: 6.986

10.  Complex mixtures of antibodies generated from a single production qualitatively and quantitatively evaluated by native Orbitrap mass spectrometry.

Authors:  Natalie J Thompson; Linda J A Hendriks; John de Kruif; Mark Throsby; Albert J R Heck
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.